Robert I Haddad MD

Oncology•Boston, MA

Head & Neck Cancer

Division Chief /Head and Neck Oncology Dana Farber Cancer Institute Professor of Medicine, Harvard Medical School

Join to View Full Profile

450 Brookline AvenueDana Farber Cancer InstituteBoston, MA 02215
Phone+1 617-632-3090
Fax+1 617-632-4448

Education & Training

University of MarylandFellowship, Hematology and Medical Oncology, 1998 - 2001
Icahn School of Medicine at Mount Sinai/Morningside/WestResidency, Internal Medicine, 1995 - 1998
St Joseph's University Medical SchoolClass of 1995

Certifications & Licensure

MA State Medical License 2001 - 2025
NH State Medical License 2024 - 2024
FL State Medical License 2020 - 2022
ME State Medical License 2020 - 2021
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2014
Boston Magazine Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2013

Clinical Trials

Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial) Start of enrollment: 2004 Aug 01
Completed
Phase 3
Randomized Amifostine For SCCHN Start of enrollment: 2003 May 01
Completed
Phase 2
Title XELOX FOR SALIVARY GLAND CANCERS Start of enrollment: 2004 Oct 01
Terminated
Phase 2
C-TPF in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2007 Jan 01
Completed
Phase 1
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck Start of enrollment: 2007 Mar 01
Completed
Phase 2
A Randomized Phase III Trial Comparing Sequential Therapy With TPF/ Chemoradiation (ST) to Cisplatinum-Based Chemoradiotherapy With Accelerated Concomitant Boost Radiotherapy (CRT) For Locally Advanced Squamous Cell Cancer of the Head and Neck ("The Parad Start of enrollment: 2004 Aug 01
Docetaxel/Cisplatin/5-Fluorouracil (TPF) Human Papillomavirus (HPV) Squamous Cell Carcinoma Study Start of enrollment: 2011 Jul 01
Terminated
Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers Start of enrollment: 2012 Sep 01
Unknown status
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Start of enrollment: 2014 May 29
Completed
Phase 3
Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer Start of enrollment: 2019 Jun 11
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

4 citations
A Phase I/II Trial of Sapanisertib in Advanced Anaplastic and Radioiodine Refractory Differentiated Thyroid Carcinoma.
Kartik Sehgal, Anthony Serritella, Mofei Liu, Anne ONeill, Chaitali Nangia
The Journal of Clinical Endocrinology and Metabolism. 2025-04-22
STELLAR-305: phase II/III study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with HNSCC.
Nabil F Saba, Kevin Harrington, Lisa Licitra, Jean-Pascal Machiels, Cixin He
Future Oncology. 2025-04-18
Epigenetic therapy sensitizes anti-PD-1 refractory head and neck cancers to immunotherapy rechallenge.
Tingting Qin, Austin K Mattox, Jean S Campbell, Jong Chul Park, Kee-Young Shin
The Journal of Clinical Investigation. 2025-03-17

Journal Articles

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma
Glenn J Hanna, Nicole Chau, Jochen Lorch, Robert I Haddad, JAMA Oncology
Genomic Correlates of Response to Immune Checkpoint Blockade in Microsatellite-Stable Solid Tumors
Jeffrey A Engelman, David A Barbie, Nicole G Chau, Glenn J Hanna, Natalie I Vokes, Sabina Signoretti, Pasi A Janne, Robert I Haddad, Lynette M Sholl, Rizwan Haq, Peter..., Nature

Other

Human papillomavirus associated head and neck cancer
Haddad RI
http://www.uptodate.com/contents/human-papillomavirus-associated-head-and-neck-cancer
UpToDate, Wolters Kluwer Health - 2013-04-15

Authored Content

Neoadjuvant Nivolumab or Nivolumab plus Ipilimumab in Untreated Oral Cavity Squamous Cell CarcinomaAugust 2020

Press Mentions

Pre- and Post-Surgery Immunotherapy Enhances Outcomes in Head and Neck CancerApril 27th, 2025
Dana-Farber Research Highlights Head and Neck, Breast, Lung, and Survivorship Studies at AACR Annual Meeting 2025April 25th, 2025
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited ResearchersNovember 19th, 2024
Join now to see all

Robert I Haddad MD

Dr. Haddad is on Doximity

Education & Training

Certifications & Licensure

Awards, Honors, & Recognition

Clinical Trials

Publications & Presentations

Authored Content

Press Mentions

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.